Azitra Receives Notice of Non-Compliance from NYSE American
Azitra (NYSE American: AZTR) received a notice of non-compliance from NYSE American on October 3, 2025 under Section 1003(a)(ii).
The rule requires listed companies with recent losses to have $4 million or more in stockholders' equity. Azitra has until October 31, 2025 to file a Plan to regain compliance by April 1, 2027. The company says it will timely submit a Plan, is exploring multiple funding avenues, and intends to complete one or more transactions to achieve compliance. Receipt of the notice does not affect current listing or trading or SEC reporting.
Azitra is a clinical-stage dermatology company with lead programs ATR-12 (Phase 1b) and ATR-04 (FDA Fast Track; open IND) and a microbial library of ~1,500 strains.
Azitra (NYSE American: AZTR) ha ricevuto una notifica di non conformità da NYSE American il 3 ottobre 2025 ai sensi della Sezione 1003(a)(ii).
La norma richiede che le società quotate con perdite recenti possano avere $4 milioni o più di patrimonio netto degli azionisti. Azitra ha tempo fino al 31 ottobre 2025 per presentare un Piano per riconquistare la conformità entro il 1 aprile 2027. L'azienda afferma che presenterà tempestivamente un Piano, sta esplorando molteplici vie di finanziamento e intende completare una o più operazioni per raggiungere la conformità. La Ricezione della notifica non influisce sull'attuale quotazione o sul trading né sulla segnalazione SEC.
Azitra è una società dermatologica in fase clinica con programmi principali ATR-12 (Fase 1b) e ATR-04 (FDA Fast Track; IND aperta) e una libreria microbica di circa 1.500 ceppi.
Azitra (NYSE American: AZTR) recibió una nota de incumplimiento de NYSE American el 3 de octubre de 2025 de acuerdo con la Sección 1003(a)(ii).
La norma exige que las empresas cotizadas con pérdidas recientes tengan $4 millones o más en patrimonio de los accionistas. Azitra tiene hasta el 31 de octubre de 2025 para presentar un Plan para recuperar el cumplimiento antes del 1 de abril de 2027. La empresa dice que presentará un Plan a tiempo, está explorando varias vías de financiación y tiene la intención de completar una o más transacciones para lograr el cumplimiento. La recepción de la nota no afecta a la cotización o al comercio actuales ni a la presentación ante la SEC.
Azitra es una empresa de dermatología en fase clínica con programas principales ATR-12 (Fase 1b) y ATR-04 (FDA Fast Track; IND abierto) y una biblioteca microbiana de ~1,500 cepas.
Azitra (NYSE American: AZTR)은 NYSE American으로부터 2025년 10월 3일에 불이행 경고를 받았습니다. 해당 규칙은 최근 손실이 있는 상장기업은 $4백만 이상의 주주지분을 보유해야 한다고 요구합니다. Azitra는 2025년 10월 31일까지 계획을 제출하여 2027년 4월 1일까지 규정 준수를 회복해야 합니다. 회사는 시한 내에 계획을 제출하고, 여러 자금 조달 경로를 모색하고 있으며, 준수를 달성하기 위해 하나 이상 거래를 마무리할 의향이 있다고 말합니다. 이 통지는 현재의 상장이나 거래 또는 SEC 보고에 영향을 미치지 않습니다.
Azitra는 ATR-12(1상 이후) 및 ATR-04(FDA Fast Track; 개방 IND) 프로젝트를 보유한 임상단계 피부과 회사이며, 약 1,500개 균주의 미생물 라이브러리가 있습니다.
Azitra (NYSE American : AZTR) a reçu un avertissement de non-conformité de la part du NYSE American le 3 octobre 2025 en vertu de la Section 1003(a)(ii).
La règle exige que les entreprises cotées ayant subi des pertes récentes disposent d'un capital des actionnaires d'au moins 4 millions de dollars. Azitra dispose jusqu'au 31 octobre 2025 pour déposer un plan afin de rétablir la conformité d'ici le 1er avril 2027. La société indique qu'elle soumettra un plan en temps voulu, explore plusieurs voies de financement et a l'intention de finaliser une ou plusieurs transactions pour atteindre la conformité. La réception de l'avis n'affecte pas la cotation ou le trading actuels ni les déclarations à la SEC.
Azitra est une société dermatologique en phase clinique avec les programmes principaux ATR-12 (Phase 1b) et ATR-04 (FDA Fast Track; IND ouvert) et une bibliothèque microbienne d'environ 1 500 souches.
Azitra (NYSE American: AZTR) erhielt am 3. Oktober 2025 von der NYSE American eine Nichteinhaltungs-Mitteilung gemäß Abschnitt 1003(a)(ii).
Die Regel verlangt, dass gelistete Unternehmen mit jüngsten Verlusten mindestens 4 Millionen US-Dollar an Eigenkapital der Aktionäre haben. Azitra hat bis zum 31. Oktober 2025, einen Plan zur Wiederherstellung der Compliance bis zum 1. April 2027 einzureichen. Das Unternehmen erklärt, fristgerecht einen Plan vorzulegen, mehrere Finanzierungsmöglichkeiten zu prüfen und beabsichtigt, eine oder mehrere Transaktionen abzuschließen, um die Einhaltung zu erreichen. Der Empfang der Mitteilung beeinträchtigt weder die aktuelle Notierung oder den Handel noch die SEC-Berichterstattung.
Azitra ist ein klinisch fortgeschrittenes Dermatologie-Unternehmen mit den Leitprogrammen ATR-12 (Phase 1b) und ATR-04 (FDA Fast Track; offene IND) sowie einer mikrobischen Bibliothek von ca. 1.500 Stämmen.
Azitra (NYSE American: AZTR) تلقّت إشعاراً بعدم الامتثال من NYSE American في 3 أكتوبر 2025 وفقاً للقسم 1003(a)(ii).
القانون يتطلب من الشركات المدرجة التي لديها خسائر حديثة امتلاك $4 مليون أو أكثر من حقوق مساهميها. لدى Azitra حتى 31 أكتوبر 2025 لتقديم خطة لاستعادة الامتثال بحلول 1 أبريل 2027. وتقول الشركة إنها ستقدّم خطة في الوقت المناسب، وتستكشف عدة سبل تمويل، وتهدف إلى إكمال صفقة أو أكثر لتحقيق الامتثال. استلام الإشعار لا يؤثر على القيد أو التداول الحاليين أو الإبلاغ لـ SEC.
Azitra هي شركة عناية بالبشرة في مرحلة السريرية مع البرامج الرئيسية ATR-12 (المرحلة 1b) و ATR-04 (FDA Fast Track؛ IND مفتوح) ومكتبة ميكروبية تقارب ~1,500 سلالة.
Azitra (NYSE American: AZTR) 于 2025年10月3日 收到 NYSE American 的 不合规通知，依据第 1003(a)(ii) 条。
该规则要求最近亏损的上市公司至少拥有 $4 百万美元 的股东权益。Azitra 需在 2025年10月31日 前提交 计划，以在 2027年4月1日 前重新达到合规状态。公司表示将按时提交计划，正在探索多种融资途径，并打算完成一项或多项交易以实现合规。收到通知并不会影响当前的上市、交易或 SEC 报告。
Azitra 是一家处于临床阶段的皮肤病学公司，主要项目为 ATR-12（1b 期）和 ATR-04（FDA 快速通道；IND 已开放），并且拥有约 1,500 条菌株 的微生物库。
- Notice does not suspend listing or trading immediately
- Deadline to submit compliance Plan: Oct 31, 2025
- FDA Fast Track designation for ATR-04 (EGFRi rash)
- Open IND for ATR-04 clinical development
- Non-compliance under Section 1003(a)(ii) notified Oct 3, 2025
- Rule requires $4 million minimum stockholders' equity
- Must regain compliance by Apr 1, 2027
- Company acknowledges need for funding/transactions to comply
Insights
Azitra received a NYSE American non-compliance notice for shareholder equity shortfall; company must submit a remediation Plan by October 31, 2025.
Azitra disclosed non-compliance with Section 1003(a)(ii) because it lacks the required $4 million minimum stockholders' equity after reporting losses in three of four recent fiscal years. The notice does not suspend trading and states the company has until October 31, 2025 to submit a Plan to regain compliance by April 1, 2027.
Why it matters: failing to meet listing standards signals a capital shortfall and triggers required remediation steps and periodic Exchange monitoring; this increases urgency for funding or transactions. Azitra explicitly states it is exploring multiple funding avenues and intends to deliver the Plan, which is the concrete action item the Exchange will review.
Monitorable item: Azitra must submit the Plan by October 31, 2025 and demonstrate compliance by April 1, 2027.
Azitra intends to timely deliver a Plan to the Exchange. If the Exchange accepts the Plan, Azitra will be notified in writing and will be subject to periodic reviews including quarterly monitoring for compliance with the Plan. Azitra is assessing and exploring multiple funding avenues and is committed to undertaking a transaction or transactions in the future to achieve compliance with the Exchange's requirements.
Receipt of the notice from the Exchange has no immediate effect on the listing or trading of Azitra's common stock on the Exchange, and does not affect Azitra's business, operations or reporting requirements with the
About Azitra
Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. The Company's lead program, ATR-12, uses an engineered strain of S. epidermidis designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. Netherton syndrome may be fatal in infancy with those living beyond a year having profound lifelong challenges. The ATR-12 program includes a Phase 1b clinical trial in adult Netherton syndrome patients. ATR-04, Azitra's additional advanced program, utilizes another engineered strain of S. epidermidis for the treatment of EGFR inhibitor ("EGFRi") associated rash. Azitra has received Fast Track designation from the FDA for EGFRi associated rash, which impacts approximately 150,000 people in the U.S. Azitra has an open IND for its ATR-04 program in patients with EGFRi associated rash. The ATR-12 and ATR-04 programs were developed from Azitra's proprietary platform of engineered proteins and topical live biotherapeutic products that includes a microbial library comprised of approximately 1,500 bacterial strains. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen the library of strains for drug like molecules. For more information, please visit https://azitrainc.com.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding Azitra's expectations regarding a period to comply with the Plan and applicable Exchange requirements, and actions of Azitra and/or the Exchange to be taken with respect to matters discussed in the notice.
Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to that we may experience delays in the dosing the first patient in this Phase 1/2 trial; our product candidates may not be effective; there may be delays in regulatory approval or changes in regulatory framework that are out of our control; our estimation of addressable markets of our product candidates may be inaccurate; we may fail to timely raise additional required funding; our actions and/or the Exchange's actions to be taken with respect to matters discussed in the notice from the Exchange; more efficient competitors or more effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are dependent on third-parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning Azitra's programs and operations are described or incorporated by reference in our annual report on Form 10-K filed with the SEC on February 24, 2025. Azitra explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Contact
Norman Staskey
Chief Financial Officer
staskey@azitrainc.com
Investor Relations
Tiberend Strategic Advisors, Inc.
Jon Nugent
205-566-3026
jnugent@tiberend.com
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
646-577-8520
cmcdonald@tiberend.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/azitra-receives-notice-of-non-compliance-from-nyse-american-302575058.html
SOURCE Azitra, Inc.
FAQ
What did Azitra (AZTR) announce on October 3, 2025 regarding NYSE American?
Why is Azitra (AZTR) non-compliant with NYSE American rules?
What is Azitra's deadline to submit a plan to NYSE American for AZTR?
By when must Azitra (AZTR) regain compliance with NYSE American if its Plan is accepted?
Does the NYSE American notice affect AZTR trading or SEC reporting immediately?
What steps is Azitra planning to take to regain NYSE compliance for AZTR?
What clinical programs did Azitra highlight in the October 3, 2025 press release?
